A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M. Vannucchi, P. Gopalakrishna, Abdel Hmissi et al.|Haematologica|2015Cited by 252
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrđan Verstovšek, H. Kantarjian, Ruben A. Mesa et al.|Haematologica|2013Cited by 162
Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanomaReinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|Annals of Oncology|2017Cited by 40
Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant MelanomaAna Arance, Keith T. Flaherty, Reinhard Dummer et al.|Annals of Oncology|2017Cited by 10
Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanomaHelen Gogas, Keith T. Flaherty, Reinhard Dummer et al.|Annals of Oncology|2017Cited by 3